Open Orphan #ORPH announces completion of the merger with hVIVO and re-admission

Open Orphan plc (ORPH), a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, is pleased to announce that admission to trading on AIM and Euronext Growth of its existing ordinary share capital and the new ordinary shares to be issued as consideration in connection with the Merger, will commence at 8.00 a.m. […]

Open Orphan #ORPH – hVIVO merger offer now wholly unconditional

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ANY SUCH JURISDICTION 17 January 2020 Recommended All Equity Offer for HVIVO PLC (“HVIVO”) to merge with OPEN ORPHAN PLC (“OPEN […]

Open Orphan #ORPH – Second Closing of the hVIVO Offer, No extension of the Offer

Second Closing of the Offer No extension of the Offer Introduction On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and to be issued share capital of hVIVO (the “Offer”). Under the terms of the Offer, hVIVO […]

Irish Independent – Open Orphan signs ‘significant’ revenue generating contract

by Ellie Donnelly Open Orphan, a Europe-focused pharma services company specialising in rare disease and so-called orphan drugs, has signed a contract with a German-based research-driven pharmaceutical company. Open Orphan said the contract guarantees “significant” annual income, with work under the deal to commence this month. This contract will see Venn Life Sciences, part of […]

Open Orphan #ORPH – Result of General Meeting

Open Orphan is pleased to announce that at the Company’s General Meeting held earlier today in relation to the Company’s proposed merger with hVIVO plc and the Proposed Placing, all of the Resolutions put to the meeting were duly passed. The Board is excited by the growth potential of the Enlarged Group following completion of […]